文献速递临床试验与 GCP

加速康复外科路径对比传统管理对腹腔镜辅助远端胃癌根治术临床结局影响的随机对照试验研究方案

Effects of perioperative enhanced recovery after surgery pathway management versus traditional management on the clinical outcomes of laparoscopic-assisted radical resection of distal gastric cancer: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-05-01

本研究为前瞻性多中心随机对照试验,计划纳入400例患者,按1:1随机分为ERAS路径组与传统管理组,主要终点为3年总生存期与无病生存期,旨在验证ERAS路径能否改善腹腔镜辅助远端胃癌根治术患者的生存预后。

要点

  • ERAS路径组围手术期按ERAS路径管理,对照组按传统模式管理。
  • 主要比较终点为两组3年总生存期与无病生存期。
  • 计划纳入400例,前瞻性多中心1:1随机分组。

核心结论

  • 该试验旨在确认ERAS路径能否改善腹腔镜辅助远端胃癌根治术患者的无病生存与总生存。
  • 目前尚缺乏ERAS路径对胃癌患者预后影响的前瞻性研究报道。

研究设计与样本

  • 前瞻性、多中心随机对照试验,设试验组与对照组,按1:1比例随机分组。
  • 计划纳入400例患者,试验组围手术期按ERAS路径管理,对照组按传统管理模式管理。

主要发现

  • 主要终点为两组3年总生存期与无病生存期的比较。
  • 研究将比较两组炎症指标、短期临床结局与生存情况。

临床怎么用

  • 若结果阳性,可为ERAS路径改善胃癌患者生存提供证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of gastric cancer in East Asia is much higher than the international average. Therefore, improving the prognosis of patients and establishing effective clinical pathways are important topics for the prevention and treatment of gastric cancer. At present, the enhanced recovery after surgery (ERAS) pathway is widely used in the field of gastric surgery. Many randomized controlled trial (RCT) studies have proven that the ERAS regimen can improve the short-term clinical outcomes of patients with gastric cancer. However, a prospective study on the effect of the ERAS pathway on the prognosis of patients with gastric cancer has not yet been reported. This trial aims to confirm whether the ERAS pathway can improve the disease-free survival and overall survival of patients undergoing laparoscopic-assisted radical resection for distal gastric cancer. METHODS/DESIGN: This study is a prospective, multicentre RCT. This experiment will consist of two groups - an experimental group and a control group - randomly divided in a 1:1 ratio. The perioperative period of the experimental group will be managed according to the ERAS pathway and that of the control group will be managed according to the traditional management mode. An estimated 400 patients will be enrolled. The main endpoint for comparison is the 3-year overall survival and disease-free survival between the two groups. DISCUSSION: The results of this RCT should clarify whether the ERAS pathway is superior to traditional treatment on inflammatory indexes, short-term clinical outcome and survival for laparoscopic-assisted radical resection of distal gastric cancer. It is hoped that our data will provide evidence that the ERAS pathway improves survival in patients with gastric cancer. TRIAL REGISTRATION: Chinese Clinical Trial Registry, CHiCTR1900022438. Registered on 11 April 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tian Y, Cao S, Li L, et al. Effects of perioperative enhanced recovery after surgery pathway management versus traditional management on the clinical outcomes of laparoscopic-assisted radical resection of distal gastric cancer: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32357913. doi:10.1186/s13063-020-04272-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。